Oncotarget

Case Reports:

Primary Sjögren’s syndrome with diffuse cystic lung changes developed systemic lupus erythematosus: a case report and literature review

PDF |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:35473-35479. https://doi.org/10.18632/oncotarget.16010

Metrics: PDF 1945 views  |   HTML 1841 views  |   ?  

Xiao Liu, Hao Li, Yunhong Yin, Dedong Ma and Yiqing Qu _

Abstract

Xiao Liu1, Hao Li1, Yunhong Yin1, Dedong Ma1 and Yiqing Qu1

1 Department of Respiratory Medicine, Qilu Hospital of Shandong University, Jinan, China

Correspondence to:

Yiqing Qu, email:

Keywords: Sjögren’s syndrome, systemic lupus erythematosus, diffuse cystic lung changes

Received: January 23, 2017 Accepted: March 02, 2017 Published: March 08, 2017

Abstract

Sjögren’s syndrome (SS) is a chronic inflammatory autoimmune disease that can occur as a unique existence (primary Sjögren’s syndrome) or merge with other systemic diseases like systemic lupus erythematosus (SLE), rheumatoid arthritis or systemic sclerosis (secondary Sjögren’s syndrome). Data on the two diseases occurrence order are inadequate. Primary Sjögren’s syndrome (pSS) may relatively uncommonly lead to diffuse cystic lung changes. We represent a female who was diagnosed pSS with diffuse cystic lung alterations developed SLE two years later. SS was diagnosed on account of the existence of dryness of eye and mouth, Schirmer’s test, biopsy of the minor salivary glands of her lip, positive anti-SSA and anti-SSB antibody in the serum. Chest computed tomography image showed bilateral diffuse cystic changes with a wide variation in cyst size and distribution. SLE was finally diagnosed based on bilateral lower limb skin rash, gonarthritis and omarthritis, low level of complement, antinuclear antibody 1:640 and positive antibodies to double-stranded DNA. Improvement was achieved with therapy of corticosteroids, hydroxychloroquine and antibiotics. This report provides us clinical, diagnosis and treatment perception of SS-onset SLE as patient presenting diffuse cystic lung changes.


INTRODUCTION

Sjögren’s syndrome (SS) is a chronic systemic disease characterized by lymphocytic infiltration of exocrine glands, it can occur as a distinct entity (primary Sjögren’s syndrome) or in association with other autoimmune diseases like systemic lupus erythematosus (SLE) (secondary Sjögren’s syndrome). When SS is concurrent with SLE, the former is commonly considered as secondary to the later although records on which to base this viewpoint are inadequate [1-7]. Some studies have shown that primary Sjögren’s syndrome (pSS) with extraglandular manifestations can precede SLE by several years [5, 8-17].

Pulmonary disease in SS has a extensive rate of 9% to 90% in different case series [18-21]. Pulmonary cysts have been reported in several studies to occur in 7.4% to 46.2% of patients with SS [18-20, 22-24]. Few studies have evaluated the nature of cystic abnormalities on chest imaging in patients with SS [18,19, 22, 25, 26]. Typical characteristics of the cystic pattern associated with SS on high resolution computed tomography (HRCT) imaging include a broad differentiation in cyst size and inner construction within cysts, positional simplification of parenchymal structure, perivascular and generally basilar dominating allocation and frequent association with ground glass opacities and nodules [26].

We show here a female patient who was diagnosed pSS with diffuse cystic lung changes developed SLE two years later. This report could be useful for coming research of diagnosis and treatment for this type of disease.

CASE PRESENTATION

A 56-year-old woman was hospitalized in Qilu Hospital of Shandong University in October 2014 because of a history of xerostomia, xerophthalmia, dry systemic skin for six years and intermittent cough, little white sputum , worsening dyspnea for three years. Physical examination revealed vesicular breath sounds in bilateral lungs. The remainder of physical examination was normal. Her laboratory work showed white blood cell (WBC) count 2100/mm3 (normal 4000-10000/mm3), neutrophil (NEU) count 1410/mm3 (normal 1800-6300/mm3), lymphocyte count 610/mm3 (normal 1100-3200/mm3), monocyte count 90/mm3 (normal 100-600/mm3), erythrocyte count 3.44×1012/L (normal 3.8-5.1×1012/L), erythrocyte sedimentation rate (ESR) 72mm/h (normal 0-18mm/h). Rheumatism laboratory examination showed anti-nuclear antibody (ANA) 1:640 positive (normal < 1:80), positive anti-SSA antibody and anti-SSB antibody (normal negative), quantitative anti-bodies to double-stranded DNA (dsDNA) 49.55 IU/ml (normal < 100IU/ml). Humoral immune test showed IgG 35 g/L (normal 7-16g/L), IgA 9.77 g/L (normal 0.7-4 g/L), C3 (complement component 3) 0.84 g/L (normal 0.9-1.8g/L), C4 (complement component 4) 0.093 g/L (normal 0.1-0.4g/L) (Table 1). Schirmer’s test showed right eye 2mm/5min and left eye 5mm/5min (normal 10-45mm/5min). Chest computed tomography (CT) showed bilateral diffuse cystic changes with a wide variation in cyst size (Figure 1A-1B). The diameter length of vesicles ranged approximately from 3.2mm to 50.2mm. Cysts were thin walled and asymmetrically distributed throughout the lung. She was diagnosed pSS with diffuse cystic lung changes. After 8 days therapy of intravenous methylprednisolone (40mg qd), hydroxychloroquine (200mg bid) and antibiotics of cefuroxime (1.5g q12h), she felt xerostomia, xerophthalmia and respiratory symptoms relieved. The blood routine indexes also showed improvement from WBC count 2100/mm3 to 3640/mm3 and from NEU count 1410/mm3 to 2399/mm3. She was discharged home and had been taking prednisone (50mg qd) with hydroxychloroquine (200mg bid). She gradually reduced dosage of prednisone to zero, and stopped taking all drugs on Feb 2016.

Then she was admitted to our hospital again in March 2016 because of the aggravation of cough, dyspnea, xerostomia and xerophthalmia after drug withdrawal. She also reported accompanying clinical symptoms of painful shoulder-joints and knee-joints in the past month. She denied fevers, chills or shivers. She did not have any surgical history. Negative family history for coronary artery disease and ovarian cancer was confirmed. She had never smoked, used alcohol or illicit drugs and had no environmental exposures. Vital signs on admission showed heart rate of 84/minute, respiration rate of 21/minute, blood pressure of 128/78mmHg, axillary temperature 36.6 oC. Physical examination revealed coarse breath sounds bilaterally. Her eyes and mouth were extremely dry. Sheet red rash was seen on bilateral lower limb skin. Swollen knee-joints were seen.

Laboratory examinations showed ANA 1:640 (normal < 1:80), dsDNA 290.51 IU/ml (normal < 100IU/ml), positive anti-SSA and anti-SSB antibody. Serologic humoral immunity showed IgG 21 g/L (normal 7-16g/L), IgA 2.94 g/L (normal 0.7-4 g/L), C3 0.63 g/L (normal 0.9-1.8g/L), and C4 0.108 g/L (normal 0.1-0.4g/L) (Table 1). Serum angiotensin-converting enzyme (SACE) was 12.40 U/L (normal 5-68U/L). Indices of urine routine test, liver function test, renal function test and tumor biomarkers were all in normal range.

CT showed asymmetrically diffuse cystic changes with a wide variation in cyst size and distribution, which was almost unchanged from 2014 (Figure 1C-1D). Schirmer’s test of her eyes revealed both eyes 0 mm/5min. Secretions of saliva were reduced. Biopsy of lower lip revealed chronic inflammation and lymphocytes infiltration of minor salivary glands (Figure 2). Pulmonary function test showed total lung capacity (TLC) 4.51L (predicted value 4.64L), vital capacity (VC) MAX 2.32L (predicted value 2.67L), forced vital capacity (FVC) 1.96L (predicted value 2.58L), forced expiratory volume in one second (FEV1) 1.34L (predicted value 2.17L), FEV1/predicted FEV1 value (FEV1%) 61.9%, FEV1/forced capacity ratio (FEV1/FVC) 68.31%, and diffusion function test showed carbon monoxide transfer factor in single breath (TLCO SB) 7.22 ml/min/mmHg (predicted value 21.78 ml/min/mmHg).

Table 1: Laboratory values of serum

Variable of Serum

First admission(2014)

Second admission(2016)

Normal range in our unit

Anti-nuclear antibody

1:640

1:640

<1:80

Anti-SSA antibody

positive

positive

negative

Anti-SSB antibody

positive

positive

negative

Antibodies to dsDNA

49.55

290.51

<100 IU/ml

White blood cell

2100

4500

(4000, 10000)/mm3

Lymphocyte

610

1650

(1100, 3200)/mm3

C3

0.84

0.63

(0.9, 1.8)g/L

C4

0.093

0.108

(0.1, 0.4)g/L

IgG

35

21

(7, 16)g/L

IgA

9.77

2.94

(7, 4)g/L

(Normal range in our unit: normal range of clinical laboratory in Qilu Hospital of Shandong University)

Figure 1:

Figure 1: A.-B. Chest high resolution computed tomography (HRCT) images in 2014 showing bilateral diffuse thin walled cystic changes with a wide variation in cyst size and distribution. C.-D. Chest HRCT images in 2016 which were almost unchanged from 2014.

Eventually, this patient was diagnosed pSS presenting diffuse cystic lung changes developed SLE. During this hospitalization, she was started on oral hydroxychloroquine (200mg bid), intravenous methylprednisolone (80mg qd) and antibiotics of sulbactam and cefoperazone (2g q12h) therapy. On the seventh day of hospitalization, pulse therapy was discontinued and she was started on oral prednisone 60 mg daily with hydroxychloroquine (200 mg bid). She felt clinical symptoms improved again and laboratory examination showed ESR decreased from 69mm/h to 18mm/h. On the tenth day of hospitalization, the dosage of prednisone was reduced to 40 mg and she was discharged home.

In this case reported here, differential diagnoses like lymphangioleiomyomatosis (LAM) were unlikely. SACE was in normal range. Besides, she did not have medical history of pneumothorax.

Histology of the little salivary glands in the lower lip revealing infiltration of lymphocytes in the glands.

Figure 2: Histology of the little salivary glands in the lower lip revealing infiltration of lymphocytes in the glands. A. (original magnification, ×100), B. (original magnification, ×200).

FOLLOW UP

The patient has been followed up for 9 months. She denied any aggravation of clinical symptoms. Hence no further imaging examinations or laboratory tests were pursued and she continued to be managed clinically.

DISCUSSION

SS is a chronic systemic inflammatory disease with lymphocytic infiltration of exocrine glands. SS can exist as a unique presence (pSS) or in combination with other systemic diseases (sSS). While salivary and lacrimal glands are most ordinarily involved, impaired mucosal defense and glandular dysfunction inside of the lung may make it more vulnerable to pulmonary inflammation [20]. The case reported here was diagnosed Sjögren’s syndrome in 2014 according to the American and European Consensus Group classification criteria (AECG-criteria) [27], and then developed SLE in 2016 based on the 2012 revision classification criteria for SLE [28]. HRCT images in 2014 and 2016 showed asymmetric multiple cysts of varying size and distribution in both lungs, and did not present an obvious progression in the size, number and distribution of cysts.

That SS can be coexistence with SLE was first reported in 1959 [29] and has since then been documented by several studies [1, 3-17, 30-41]. Reports indicated that 3.7%-19.6% SLE patients were accompanying SS [2, 4, 34-36]. However, rare published reports identified time sequence that pSS preceded SLE [5, 8-17] or SLE preceded SS [4-7] (Table 2). We generally comprehend specific clinical, laboratory, treatment and prognosis features that distinguish SLE-onset SS and SS-onset SLE from SS or SLE only patients. SLE-onset SS were older at SLE diagnosis, showed lower mortality and improved survival estimates when compared with SLE-only patients [4, 34]. SS-onset SLE were significantly older, showed a higher frequency of Raynaud’s phenomenon, anti-SSA and anti-SSB, a lower frequency of severe renal involvement and lower mortality, and presented comparatively stable disease course and benign prognosis that required less vigorous treatment with glucocorticoids and/or immunosuppressant when compared with SLE-only patients [5, 11, 12]. SS-onset SLE were younger and had an increased frequency of arthritis, xerostomia, anticardiolipin antibodies and low levels of C3 and C4 in the serum, perivascular infiltrates in the salivary glands but a lower frequency of interstitial lung disease when compared with SS-only [11, 13].

Table 2: Summary of SS-SLE articles that identified time sequence of SS and SLE

Reference

Brief

Nossent et al. [4]

27 patients developed SS after a mean period of 48 months of 138 SLE patients.

BAER et al. [5]

In a group of 259 SS-SLE patients, SS preceded SLE by more than 1 year in 32 patients and SLE preceded SS in 207 patients.

Hernández-Molina et al. [6]

19 SLE-onset SS were diagnosed in a prospective cohort of 103 SLE patients.

Derk et al. [7]

A 57-year-old woman who was diagnosed SLE 16 years earlier and was diagnosed with sSS one year later.

Chevalier et al. [8]

A 41-year-old female who developed SLE 7 years after pSS.

Jodo et al. [9]

A 43-year-old female who had been diagnosed as pSS since 1986, then diagnosed SLE in 1990.

Zufferey et al. [10]

4 of 55 SS patients developed SLE (7.5%) after a mean follow-up of 12 years.

Manoussakis et al. [11]

In a cohort study of 283 SLE patients, SS preceded SLE in 18 of 26 SS-SLE.

Xu et al. [12]

A case control study of 41 SS-onset SLE and 214 SLE-only patients.

Yang et al. [13]

A case control study of 55 SS-onset SLE and 55 pSS patients.

Pan et al. [14]

In a group of 542 SLE patients, 17 of 35 SS-SLE showed pSS preceded SLE.

Taşdemir et al. [15]

A 16-year-old girl progressed SLE after 6 years diagnosis of SS.

Szanto et al. [16]

In a group of 56 SS-SLE patients, 8 presented SS preceding SLE by 1-18 years, and 22 presented SLE preceding SS by 1-19 years.

Satoh et al. [17]

A 69-year-old woman developed SLE after 10 years diagnosis of pSS.

SS, Sjögren’s syndrome; pSS, primary Sjögren’s syndrome; sSS, secondary Sjögren’s syndrome.

Cystic lung disease (CLD) have been reported in several studies to occur in 7.4% to 46.2% of patients with SS [18-20, 22-24], and the finding of cyst-only disease appears rare [19, 20, 24, 41]. Only one study evaluated radiologic progression of CLD in SS, finding no progression in the size and number of cysts or pulmonary function decline in most individuals after a median 4-year follow-up [24]. The proof supporting a particular pathologic relevance of CLD in SS is insufficient. Two retrospective studies found that all individuals had cysts and nodules on imaging, one of those targeting 8 individuals with known lung amyloidosis and another showing 5 individuals suffering a known lymphoproliferative disorder [43, 44]. Besides, one retrospective study of 187 patients with biopsy-proven pulmonary amyloidosis showed that 11.2% presented CLD and a strong relevance with SS [45]. Another retrospective study evaluated 22 patients, 11 of which had SS, with LIP proven by biopsy: all patients had centrilobular nodules and ground-glass attenuation, seven had cysts [46]. And one study showed association of lymphoproliferative disorders, which defined as light-chain amyloidosis, monoclonal gammopathy, or malignant lymphoma with CLD [19], but this is not inconsistent with another study which found that CT patterns unlike nonspecific interstitial pneumonia (NSIP) rarely played a role in the prediction of a pathologic diagnosis [47].

Diffuse cystic lung disease (DCLD) is an uncommon clinical and radiographic presentation with a broad differential diagnosis [48]. Although diseases like LAM, pulmonary Langerhans cell histiocytosis and Birt-Hogg-Dubé syndrome continue to be the prototypical diffuse cystic pulmonary disorders most generally encountered in treatment centers or by pathologists [49, 50], cystic lung changes as the forme fruste of SS should also be concerned. Few studies have evaluated the characteristics of cystic abnormalities on chest radiographic testing in patients with SS [18, 19, 22, 25, 26]. It has been covered that the cystic pattern relating to SS has a typical manifestation on HRCT imaging. Characteristic features include a broad differentiation in cyst size and number, inner construction within cysts, perivascular and basilar predominant allocation, positional simplification of parenchymal structure generating a ‘dissolving lung appearance’ and frequent association with ground glass opacities and nodules [26]. Those discoveries can be characteristic enough to reduce the necessity for pulmonary biopsy even in defect of proved serologic results or salivary glands biopsy, especially in patients who cannot be tolerant of invasive diagnostic test.

We reported here a patient of pSS with diffuse cystic lung alterations developed SLE, no other reports have described both the SS-onset SLE and diffused cystic lung changes in one patient in details so far. The accurate cause of emerging SLE in patients with SS has not been well known yet. It is a pity that this patient did not perform laboratory and imaging test during 2014-2016 due to some private reasons so that we could not retrieve the dynamic profiles of laboratory parameters levels and imaging changes. While confirmatory invasive tests (bronchoalveolar lavage, transbronchial biopsy, surgical lung biopsy and so on) could not be carried out on this patient because of her difficulty in tolerating invasive procedure, we conjecture that lymphocytic interstitial pneumonia or NSIP is the most likely histopathology pattern upon imaging manifestations and beneficial response to prednisone therapy.

In summary, pSS with diffuse asymmetrical cystic lung changes can precede SLE by several years. When encounter patients of pSS with diffuse cystic lung manifestation emerging clinical and laboratory features of SLE, we should consider the possibility of emergence of SLE several years later. However, more clinical research is needed to establish definitive diagnosis criterion and effective treatment for those cases.

CONFLICTS OF INTEREST

There is no conflict of interest.

REFERENCES

1. Moutsopoulos HM, Klippel JH, Pavlidis N, Worf RO, Sweet JB, Steinberg AD, Chu FC, Tarpley TM. Correlative histologic and serologic findings of sicca syndrome in patients with systemic lupus erythematosus. Arthritis Rheum. 1980; 23:36-40.

2. Andonopoulos AP, Skopouli FN, Dimou GS, Drosos AA, Moutsopoulos HM. Sjögren’s syndrome in systemic lupus erythematosus. J Rheumatol. 1990; 17:201-4.

3. Alarcón-Segovia D, Ibáñez G, Velázquez-Forero F, Hernández-Ortíz J, González-Jiménez Y. Sjögren’s syndrome in systemic lupus erythematosus. Clinical and subclinical manifestations. Ann Intern Med. 1974; 81:577-83.

4. Nossent JC, Swaak AJ. Systemic lupus erythematosus VII: frequency and impact of secondary Sjögren’s syndrome. Lupus. 1998; 7:231-4.

5. Baer AN, Maynard JW, Shaikh F, Magder LS, Petri M. Secondary Sjögren’s syndrome in systemic lupus erythematosus defines a distinct disease subset. J Rheumatol. 2010; 37:1143-9.

6. Hernández-Molina G, Zamora-Legoff T, Romero-Díaz J, Nuñez-Alvarez CA, Cárdenas-Velázquez F, Hernández-Hernández C, Calderillo ML, Marroquín M, Recillas-Gispert C, Ávila-Casado C, Sánchez-Guerrero J. Predicting Sjögren’s syndrome in patients with recent-onset SLE. Rheumatology (Oxford). 2013; 52:1438-42.

7. Derk CT, Vivino FB, Kenyon L, Mandel S. Inclusion body myositis in connective tissue disorders: case report and review of the literature. Clin Rheumatol. 2003; 22:324-8.

8. Chevalier X, de Bandt M, Bourgeois P, Kahn MF. Primary Sjögren’s syndrome preceding the presentation of systemic lupus erythematosus as a benign intracranial hypertension syndrome. Ann Rheum Dis. 1992; 51:808-9.

9. Jodo S, Sagawa A, Ogura N, Atsumi T, Amasaki Y, Nakabayashi T, Watanabe I, Mukai M, Fujisaku A, Nakagawa S. A case of systemic lupus erythematosus (SLE) developing pan-dysautonomia. Ryumachi. 1992; 32:58-65.

10. Zufferey P, Meyer OC, Bourgeois P, Vayssairat M, Kahn MF. Primary systemic Sjögren’s syndrome (SS) preceding systemic lupus erythematosus: a retrospective study of 4 cases in a cohort of 55 SS patients. Lupus. 1995; 4:23-7.

11. Manoussakis MN, Georgopoulou C, Zintzaras E, Spyropoulou M, Stavropoulou A, Skopouli FN, Moutsopoulos HM. Sjögren’s syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjögren’s syndrome. Arthritis Rheum. 2004; 50:882-91.

12. Xu D, Tian X, Zhang W, Zhang X, Liu B, Zhang F. Sjogren’s syndrome-onset lupus patients have distinctive clinical manifestations and benign prognosis: a case-control study. Lupus. 2010; 19:197-200.

13. Yang Y, Li Z, Wang L, Zhang F. The clinical and laboratory characteristics of Sjögren’s syndrome that progresses to systemic lupus erythematosus: a retrospective case-control study. Int J Rheum Dis. 2013; 16:173-7.

14. Pan HF , Ye DQ, Wang Q, Li WX, Zhang N, Li XP, Xu JH, Dai H. Clinical and laboratory profiles of systemic lupus erythematosus associated with Sjögren syndrome in China: a study of 542 patients. Clin Rheumatol. 2008; 27:339-43.

15. Taşdemir M, Hasan C, Ağbaş A, Kasapçopur Ö, Canpolat N, Sever L, Çalışkan S. Sjögren’s syndrome associated with systemic lupus erythematosus. Turk Pediatri Ars. 2016; 51:166-168.

16. Szanto A, Szodoray P, Kiss E, Kapitany A, Szegedi G, Zeher M. Clinical, serologic, and genetic profiles of patients with associated Sjögren’s syndrome and systemic lupus erythematosus. Hum Immunol. 2006; 67:924-30.

17. Satoh M, Yamagata H, Watanabe F, Nakayama S, Ogasawara T, Tojo T, Akizuki M. Development of anti-Sm and anti-DNA antibodies followed by clinical manifestation of systemic lupus erythematosus in an elderly woman with long-standing Sjögren’s syndrome. Lupus. 1995; 4:63-5.

18. Lohrmann C, Uhl M, Warnatz K, Ghanem N, Kotter E, Schaefer O, Langer M. High-resolution CT imaging of the lung for patients with primary Sjogren’s syndrome. Eur J Radiol. 2004; 52:137-43.

19. Watanabe M, Naniwa T, Hara M, Arakawa T, Maeda T. Pulmonary manifestations in Sjogren’s syndrome: correlation analysis between chest computed tomographic findings and clinical subsets with poor prognosis in 80 patients. J Rheumatol. 2010; 37:365-73.

20. Uffmann M, Kiener HP, Bankier AA, Baldt MM, Zontsich T, Herold CJ. Lung manifestation in asymptomatic patients with primary Sjögren’s syndrome: assessment with high resolution CT and pulmonary function tests. J Thorac Imaging. 2001; 16:282-9.

21. Strimlan CV, Rosenow EC 3rd, Divertie MB, Harrison EG Jr. Pulmonary manifestations of Sjögren’s syndrome. Chest. 1976; 70:354-61.

22. Matsuyama N, Ashizawa K, Okimoto T, Kadota J, Amano H, Hayashi K. Pulmonary lesions associated with Sjogren’s syndrome: radiographic and CT findings. Br J Radiol. 2003; 76:880-4.

23. Koyama M, Johkoh T, Honda O, Mihara N, Kozuka T, Tomiyama N, Hamada S, Nakamura H. Pulmonary involvement in primary Sjögren’s syndrome: spectrum of pulmonary abnormalities and computed tomography findings in 60 patients. J Thorac Imaging. 2001; 16:290-6.

24. Martínez-Balzano CD, Touray S, Kopec S. Cystic Lung Disease Among Patients With Sjögren Syndrome: Frequency, Natural History, and Associated Risk Factors. Chest. 2016; 150:631-9.

25. Gupta N, Vassallo R, Wikenheiser-Brokamp KA, McCormack FX. Diffuse Cystic Lung Disease. Part II. Am J Respir Crit Care Med. 2015; 192:17-29.

26. Gupta N, Wikenheiser-Brokamp KA, Fischer A, McCormack FX. Diffuse Cystic Lung Disease as the Presenting Manifestation of Sjögren’s Syndrome. Ann Am Thorac Soc. 2016; 13:371-5.

27. Vitali C, Bombardieri S, Jonsson R, Moutsolos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH; European Study Group on Classification Criteria for Sjögren’s Syndrome. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002; 61:554-8.

28. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64:2677–86.

29. Heaton JM. Sjögren’s syndrome and systemic lupus erythematosus. BMJ. 1959; 1:466–69.

30. Moutsopoulos HM, Chused TM, Mann DL , Klippel JH, Fauci AS, Frank MM, Lawley TJ, Hamburger MI. Sjögren’s syndrome (Sicca syndrome): current issues. Ann Intern Med. 1980; 92:212-6.

31. Steinberg AD, Talal N. The coexistence of Sjögren’s syndrome and systemic lupus erythematosus. Ann Intern Med. 1971; 74:55-61.

32. Grennan DM, Ferguson M, Williamson J, Mavrikakis M, Dick WC, Buchanan WW. Sjogren’s syndrome in SLE: Part I. The frequency of the clinical and subclinical features of Sjogren’s syndrome in patients with SLE. N Z Med J. 1977; 86:374-6.

33. Grennan DM, Ferguson M, Ghobarey AE, Williamson J, Dick WC, Buchanan WW. Sjogren’s syndrome in SLE: Part 2. An examination of the clinical significance of Sjogren’s syndrome by comparison of its frequency in typical and atypical forms of SLE, overlap syndromes and scleroderma. N Z Med J. 1977; 86:376-9.

34. Gilboe IM, Kvien TK, Uhlig T, Husby G. Sicca symptoms and secondary Sjögren’s syndrome in systemic lupus erythematosus: comparison with rheumatoid arthritis and correlation with disease variables. Ann Rheum Dis. 2001; 60:1103-9.

35. Jia Y, Liu X, Liu C, Li Z. The clinical and laboratory features of patients with Sjogren’s syndrome associated with systemic lupus erythematosus. Chin J Rheumatol. 2006; 10:23–6.

36. McDonagh JE, Isenberg DA. Development of additional autoimmune diseases in a population of patients with systemic lupus erythematosus. Ann Rheum Dis. 2000; 59:230–2.

37. Amador-Patarroyo MJ, Arbelaez JG, Mantilla RD, Rodriguez-Rodriguez A, Cárdenas-Roldán J, Pineda-Tamayo R, Guarin MR, Kleine LL, Rojas-Villarraga A, Anaya JM. Sjögren’s syndrome at the crossroad of polyautoimmunity. J Autoimmun. 2012; 39:199-205.

38. Okada A, Yoshida T, Takemura K, Ishigaki K, Shimizu A, Takano H. Successful Detection of Renal Involvement in Sjögren’s Syndrome Secondary to Systemic Lupus Erythematosus by Renal Biopsy. Intern Med. 2015; 54:1265-71.

39. Azarisman SM, Heselynn H. Systemic lupus erythematosus presenting as parotitis and secondary Sjögren’s syndrome. Singapore Med J, 2007: 48:e60-1.

40. Onishi S, Nagashima T, Kimura H, Matsuyama Y, Yoshio T, Minota S. Systemic lupus erythematosus and Sjögren’s syndrome induced in a case by interferon-alpha used for the treatment of hepatitis C. Lupus. 2010; 19:753-5.

41. Al Attia HM, D’Souza MS. Antitopoisomerase I antibody in patients with systemic lupus erythematosus/sicca syndrome without a concomitant scleroderma: two case reports. Clin Rheumatol. 2003; 22:70-2.

42. Jagirdar J, Chikkamuniyappa S, Sirohi D, McCarthy MJ, Peters JI. Cystic lung lesions in Sjogren syndrome: analysis of lymphocyte subsets in tissue with clinico-radiologic-pathologic correlation. Ann Diagn Pathol. 2013; 17:113-6.

43. Jeong YJ, Lee KS, Chung MP, Han J, Chung MJ, Kim KI, Seo JB, Franquet T. Amyloidosis and lymphoproliferative disease in Sjögren syndrome: thin-section computed tomography findings and histopathologic comparisons. J Comput Assist Tomogr. 2004; 28:776-81.

44. Baqir M, Kluka EM, Aubry MC, Hartman TE, Yi ES, Bauer PR, Ryu JH. Amyloid-associated cystic lung disease in primary Sjögren’s syndrome. Respir Med. 2013; 107:616-21.

45. Zamora AC, White DB, Sykes AM, Hoskote SS, Moua T, Yi ES, Ryu JH. Amyloid-associated cystic lung disease. Chest. 2016; 149:1223-33.

46. Johkoh T, Muller NL, Pickford HA, Hartman TE, Ichikado K, Akira M, Honda O, Nakamura H. Lymphocytic interstitial pneumonia: thin-section CT findings in 22 patients. Radiology. 1999; 212:567-72.

47. Ito I, Nagai S, Kitaichi M, Nicholson AG, Johkoh T, Noma S, Kim DS, Handa T, Izumi T, Mishima M. Pulmonary manifestations of primary Sjogren’s syndrome: a clinical, radiologic, and pathologic study. Am J Respir Crit Care Med. 2005; 171:632-8.

48. Gupta N, Vassallo R, Wikenheiser-Brokamp KA, McCormack FX. Diffuse Cystic Lung Disease. Part I. Am J Respir Crit Care Med. 2015; 191:1354-66.

49. Richards JC, Lynch DA, Chung JH. Cystic and Nodular Lung Disease. Clin Chest Med. 2015; 36:299-312.

50. Clarke BE. Cystic lung disease. J Clin Pathol. 2013; 66:904-8.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16010